<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622084</url>
  </required_header>
  <id_info>
    <org_study_id>P32203</org_study_id>
    <nct_id>NCT05622084</nct_id>
  </id_info>
  <brief_title>The Inperia Advance Post-Market Retrospective Study</brief_title>
  <official_title>Inperia Advance Carbostent™ for Infra-popliteal Artery Stenosis. Evaluation of Safety and Performance in Everyday Clinical Practice: The Inperia Advance Post-Market Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CID S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditrial Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CID S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of&#xD;
      infra-popliteal artery stenosis. The aim of this post-market retrospective study protocl&#xD;
      P32203 is to collect clinical data of patients treated with Inperia Advance for the treatment&#xD;
      of infra-popliteal artery stenosis in routine clinical practice. In order to obtain long-term&#xD;
      follow-up data, the data collection will be limited to patients that have been treated with&#xD;
      the device at least 12 months prior to the study start.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this post-market study is to systematically collect retrospective clinical&#xD;
      data on the implantable medical device Inperia Advance in the daily clinical practice in an&#xD;
      unselected population treated within the intended use. Data will be collected via medical&#xD;
      chart review in anonymous form to assess the safety and efficacy of Inperia Adavance. The&#xD;
      Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of&#xD;
      infra-popliteal artery stenosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Major Adverse Events (MAE)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite endpoint of all causes of death, unplanned target limb major amputation and/or clinically indicated target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Primary patency is defined as absence of clinically-driven target lesion revascularization or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) &gt;2.4 (Duplex Ultrasound evaluation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb-salvage rate (LSR)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Limb-salvage rate (LSR) is defined as rate of patients free from major amputation. Major amputation is defined as at or above ankle, as opposed to minor amputation being at or below metatarsus preserving functionality of foot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary patency</measure>
    <time_frame>6 months and 12 months or latest patency data available</time_frame>
    <description>Patency following successful target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days</time_frame>
    <description>Death within 30 days of the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Lesion Revascularization</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Clinically driven Target Lesion Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target limb ischemia</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Target limb ischemia requiring surgical intervention or surgical repair of target vessel rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford category measurement</measure>
    <time_frame>pretreatment, 6 months and 12 months</time_frame>
    <description>Rutherford category measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Serious Adverse Events (SAEs)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Evaluation of Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success (device and procedural) within discharge</measure>
    <time_frame>24/72 hours</time_frame>
    <description>Clinical device success defined as successful delivery and deployment of the stent(s) at the intended target lesion (this includes successful delivery and deployment of multiple stents) and final residual stenosis of the target lesion minor or equal to 30%, assessed by visual estimation and clinical device success without the occurrence of MAE during the hospital stay</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inperia Advance</intervention_name>
    <description>Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients implanted with at least one Inperia Advance stent for treatment of infra-popliteal&#xD;
        artery stenosis, at least 12 months prior to the start date of the retrospective data&#xD;
        collection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has been implanted with at least one Inperia Advance device according to the&#xD;
             indications described in the Instructions for Use (IFU).&#xD;
&#xD;
          -  Study device implantation date is at least one year (12 months) prior to the starting&#xD;
             date of the retrospective anonymous data collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated less than 12 months prior to study start&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Franco Vallana, MD</last_name>
    <phone>+39 0161 18261</phone>
    <email>franco.vallana@alvimedica.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Tocchi, MD</last_name>
    <email>m.tocchi@meditrial.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nabil Chakfe, MD</last_name>
      <email>Nabil.Chakfe@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.alvimedica.com/</url>
    <description>Manufactured website</description>
  </link>
  <link>
    <url>http://www.meditrial.net/</url>
    <description>Clinical Research Organization</description>
  </link>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 11, 2022</last_update_submitted>
  <last_update_submitted_qc>November 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

